Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
30 mars 2023 16h01 HE
|
Biora Therapeutics, Inc.
Biora initiating preclinical testing with pharma collaborator’s molecule following recent data exceeding the company’s target bioavailability levels for systemic therapeutics platform No adverse...
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
23 mars 2023 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report fourth...
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
23 févr. 2023 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced preliminary results from...
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
16 févr. 2023 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced preliminary results from...
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
19 janv. 2023 16h05 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today presented detailed results from its PM-611...
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
09 janv. 2023 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced feedback from the United States...
Biora Therapeutics Announces Reverse Stock Split
30 déc. 2022 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will effect a reverse stock...
Biora Therapeutics Announces Two Poster Presentations at the Crohn’s & Colitis Congress
08 déc. 2022 16h05 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced acceptance of two abstracts...
Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
29 nov. 2022 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed an agreement to...
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
14 nov. 2022 16h01 HE
|
Biora Therapeutics, Inc.
Presented results of human study at the American College of Gastroenterology annual meeting, demonstrating promising device performance in active ulcerative colitis patients Executed a...